Fig. 4

Suppression of salivary gland inflammation and fibrosis in LAT mice by CCL8 neutralizing therapy. A H&E staining of salivary glands in LAT mice treated with anti-CCL8 neutralizing antibody (anti-CCL8 Ab) or control immunoglobulin (control Ig). The boxed areas in the upper panels are shown magnified in the lower panels (scale bars: upper; 200 μm; lower, 100 μm). Representative images of 3 mice. B Comparison of focus score in salivary glands between anti-CCL8 Ab-treated LAT mice and control Ig-treated LAT mice. C M&T staining of salivary glands in LAT mice treated with anti-CCL8 Ab or control Ig. The boxed areas in the upper panels are magnified in the lower panels (scale bars: upper, 200 μm; lower, 100 μm). Representative images of 3 mice. D Comparison of fibrosis score in salivary glands of anti-CCL8 Ab-treated LAT mice and control Ig-treated LAT mice. E The salivary glands slices of LAT mice treated with anti-CCL8 Ab or control Ig were stained for CD4 (green) and B220 (red). DAPI (blue), 4′6-diamino-2-phenylindole (scale bars, 50 μm). F The average of CD4-positive cells per 60× magnification area. Three areas per mouse were counted. G The average of B220-positive cells per × 60 magnification area. Three areas per mouse were counted. H Salivary glands slices of LAT mice treated with anti-CCL8 Ab or control Ig were stained for CD138. Counterstaining was done with hematoxylin (scale bars: upper, 200 μm; lower, 100 μm). I The average of CD138-positive cells per high power field. Three areas per mouse were counted. The data are presented as the means ± SEMs of 3 mice. *p < 0.05, unpaired t test